Engineered Exosomes Containing Cathelicidin/LL-37 Exhibit Multiple Biological Functions.
Su. Yajuan Y; Sharma. Navatha Shree NS; John. Johnson V JV; Ganguli-Indra. Gitali G; Indra. Arup K AK; Gombart. Adrian F AF; Xie. Jingwei J
Key Findings
- Engineered exosomes contain much higher levels of LL‑37 than normal exosomes
- LL‑37‑rich exosomes kill bacteria in lab tests
- They promote blood‑vessel‑like tube formation and skin cell growth and movement
Practical Outcomes
- At this stage the work is a proof‑of‑concept and not a DIY protocol. It shows that delivering LL‑37 via exosomes could be a future therapeutic route, but producing such exosomes requires specialized lab techniques and equipment.
Summary
Scientists made tiny vesicles (exosomes) from immune cells that were loaded with a natural antimicrobial peptide called LL‑37. These boosted exosomes can kill bacteria and help blood vessels and skin cells grow, suggesting they could be used for infection control and wound healing, but the method is complex and not ready for personal use.
Abstract
Exosomes show great potential in diagnostic and therapeutic applications. Inspired by the human innate immune defense, herein, we report engineered exosomes derived from monocytic cells treated with immunomodulating compounds 1α,25-dihydroxyvitamin D<sub>3,</sub> and CYP24A1 inhibitor VID400 which are slowly released from electrospun nanofiber matrices. These engineered exosomes contain significantly more cathelicidin/LL-37 when compared with exosomes derived from either untreated cells or Cathelicidin Human Tagged ORF Clone transfected cells. In addition, such exosomes exhibit multiple biological functions evidenced by killing bacteria, facilitating human umbilical vein endothelial cell tube formation, and enhancing skin cell proliferation and migration. Taken together, the engineered exosomes developed in this study can be used as therapeutics alone or in combination with other biomaterials for effective infection management, wound healing, and tissue regeneration.
Study Information
pubmed
2022
2022-08-12T00:00:00.000Z
10.1002/adhm.202200849
12
4